Sign In
Buy INCY
$97.98
+5.74 (+6.22%)
At Close: Jun 03, 2026
Cramer reveals 5 undervalued stocks that are must-own heading into 2026
03:15pm, Wednesday, 24'th Sep 2025
Famed investor Jim Cramer says investors shouldn't feel boxed out of the market as the benchmark S&P 500 index continued to print higher highs in the second half of 2025. “Sometimes, it can feel l
Incyte Announces the Appointment of Dave Gardner as Executive Vice President and Chief Strategy Officer
07:30am, Monday, 22'nd Sep 2025
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Announces the Appointment of Dave Gardner as Executive Vice President and Chief Strategy Officer.
3 Potential Biotech Acquisition Targets
12:53pm, Friday, 19'th Sep 2025
There has been some speculation on Seeking Alpha recently on several biotech/biopharma names that make logical buyout targets. Many firms are on their way to success as standalone entities and have go
INCY Obtains FDA Approval for Label Expansion of Ruxolitinib Cream
10:55am, Friday, 19'th Sep 2025
Incyte secures FDA nod for Opzeluras pediatric use in atopic dermatitis, marking its third U.S. approval and boosting sales momentum.
US FDA approves Incyte's eczema treatment for pediatric patients
04:29pm, Thursday, 18'th Sep 2025
The U.S. Food and Drug Administration has approved Incyte's eczema treatment for children aged between 2 and 11 years, the company said on Thursday.
Incyte Announces Additional FDA Approval of Opzelura® (Ruxolitinib) Cream in Children Ages 2-11 with Atopic Dermatitis
04:21pm, Thursday, 18'th Sep 2025
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Announces Additional FDA Approval of Opzelura® (Ruxolitinib) Cream in Children Ages 2-11 with Atopic Dermatitis.
INCY Announces New Late-Stage Data on Skin Disease Drug
10:41am, Wednesday, 17'th Sep 2025
Incyte's povorcitinib shows strong 24-week STOP-HS data in hidradenitis suppurativa, supporting 2025-2026 regulatory filings.
Incyte Announces New 24-Week Phase 3 Data from the STOP-HS Clinical Trial Program of Povorcitinib in Hidradenitis Suppurativa at EADV 2025
01:00am, Wednesday, 17'th Sep 2025
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #EADV25--Incyte Announces New 24-Week Phase 3 Data from the STOP-HS Clinical Trial Program of Povorcitinib in Hidradenitis Suppurativa at EADV 2025.
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte to Present New Data Highlighting Progress Across its Dermatology Pipeline at the EADV 2025 Congress.
Incyte Corporation (INCY) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
01:46pm, Tuesday, 09'th Sep 2025
Incyte Corporation (NASDAQ:INCY ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 10:00 AM EDT Company Participants William Meury - CEO, President & Director Steven Stein - E
Just What The Doctor Ordered: This Medical Stock Offers Fresh Entry Amid 60% Rally
11:01am, Friday, 05'th Sep 2025
Stocks with healthy profits are usually rewarded with strong price gains. And this medical stock is offering a fresh entry amid a 60% run.
Incyte Corporation (INCY) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 (Transcript)
04:13pm, Thursday, 04'th Sep 2025
Incyte Corporation (NASDAQ:INCY ) Wells Fargo 20th Annual Healthcare Conference 2025 September 4, 2025 8:45 AM EDT Company Participants William Meury - CEO, President & Director Pablo Cagnoni - Presid
Incyte Corporation (INCY) Presents At Cantor Global Healthcare Conference 2025 Transcript
11:38am, Wednesday, 03'rd Sep 2025
Incyte Corporation (NASDAQ:INCY ) Cantor Global Healthcare Conference 2025 September 3, 2025 8:00 AM EDT Company Participants William Meury - CEO, President & Director Pablo Cagnoni - President and He
Incyte Launches HS TRUTHS to Spotlight the True Lived Experience of Hidradenitis Suppurativa
09:15am, Wednesday, 03'rd Sep 2025
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #HSTRUTHS--Incyte Launches HS TRUTHS to Spotlight the True Lived Experience of Hidradenitis Suppurativa.
Incyte: Wall Street Underestimates Strength Of Ruxolitinib Portfolio
09:30am, Saturday, 30'th Aug 2025
Incyte's share price continues to soar despite Trump's repeated threats to cut drug prices. One of the key reasons behind the continued upward momentum was Incyte's strong financial results for Q2 202
